221 Digital assessment of stromal B cell aggregates as a biomarker of response to immune checkpoint inhibition in unresectable melanoma

221 Digital assessment of stromal B cell aggregates as a biomarker of response to immune checkpoint inhibition in unresectable melanoma

Bibliographic Details
Main Authors:	Katherine S Panageas, Yanyun Li, Margaret K Callahan, James W Smithy, Andrea P Moy, Ronglai Shen, Fiona Ehrich, Colleen Maher, Jasme Lee, Xiyu Peng, Nathaniel Aleynick, Mingqiang Zhuang, Travis Hollmann
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

1303 Spatial topic modeling of tumor microenvironment with multiplexed imaging
by: Katherine S Panageas, et al.
Published: (2023-11-01)

128 staRgate: a flexible density-based automated gating pipeline for complex high-dimensional flow cytometry data
by: Matthew Adamow, et al.
Published: (2023-11-01)

135 Integration of T-cell activation and tumor mutation burden predicts anti-PD-1 response
by: Matthew Adamow, et al.
Published: (2023-11-01)

Unresectable gastrointestinal stromal tumors
by: Prema Menon, et al.
Published: (2011-01-01)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
by: Mohamed A. Abd El Aziz, et al.
Published: (2020-10-01)

Cross-platform dataset of multiplex fluorescent cellular object image annotations
by: Nathaniel Aleynick, et al.
Published: (2023-04-01)

Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
by: Giulio Metro, et al.
Published: (2021-09-01)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
by: Doris Helbig, et al.
Published: (2022-11-01)

Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma
by: Alessandro Rizzo, et al.
Published: (2021-01-01)

Bayesian network-driven clustering analysis with feature selection for high-dimensional multi-modal molecular data
by: Yize Zhao, et al.
Published: (2021-03-01)

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
by: Chaoyong Shen, et al.
Published: (2014-11-01)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
by: Nobukazu Fujimoto, et al.
Published: (2020-05-01)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
by: Yee Chao, et al.
Published: (2020-10-01)

Systemic Chemotherapy with Combination of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor in Unresectable Hepatocellular Carcinoma
by: Hye Yeon Chon
Published: (2024-02-01)

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
by: Zhang JX, et al.
Published: (2022-03-01)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
by: Xiaomi Li, et al.
Published: (2022-12-01)

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
by: Pei-Chang Lee, et al.
Published: (2022-06-01)

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation
by: J Wilson, et al.
Published: (2005-07-01)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
by: Hongyu Pan, et al.
Published: (2025-03-01)

Combination of DNA Vaccine and Immune Checkpoint Blockades Improves the Immune Response in an Orthotopic Unresectable Glioblastoma Model
by: Mathilde Bausart, et al.
Published: (2022-05-01)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
by: Liwei Sun, et al.
Published: (2022-09-01)

Cover_221
Published: (2022-09-01)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
by: Ryan H. Moy, et al.
Published: (2018-02-01)

Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan
by: Mitsunobu Otsuru, et al.
Published: (2024-07-01)

Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma
by: Jiajia Du, et al.
Published: (2024-01-01)

Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy
by: Chi-Leung Chiang, et al.
Published: (2019-11-01)

Deep learning of pretreatment multiphase CT images for predicting response to lenvatinib and immune checkpoint inhibitors in unresectable hepatocellular carcinoma
by: Nan-Qing Liao, et al.
Published: (2024-12-01)

Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers
by: Elvelyn R. Fernandez, et al.
Published: (2023-10-01)

Early C‐reactive Protein Kinetics Predict Response to Immune Checkpoint Blockade in Unresectable Hepatocellular Carcinoma
by: Qin Q, et al.
Published: (2023-11-01)

Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis
by: Shouhao Zhou, et al.
Published: (2023-02-01)

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
by: Jie Zhao, et al.
Published: (2022-10-01)

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab
by: Kei Endo, et al.
Published: (2022-08-01)

Changes in Serum Interleukin-8 Levels Predict Response to Immune Checkpoint Inhibitors Immunotherapy in Unresectable Hepatocellular Carcinoma Patients
by: Zhang J, et al.
Published: (2024-05-01)

Editorial 22.1
by: Natália Valadares Lima, et al.
Published: (2013-07-01)

Abteilung 221, Produktanalytik
by: Bruno Wampfler
Published: (1995-06-01)

Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
by: Kimberly Loo, et al.
Published: (2022-01-01)

miRNA‐221 and miRNA‐222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours
by: Michaela Angelika Ihle, et al.
Published: (2015-08-01)

Dynamic Changes of Neutrophil-to-Lymphocyte Ratio on Predicting Response of Immune Checkpoint Inhibitors Plus Targeted Therapies for Unresectable Hepatocellular Carcinoma
by: Yang J, et al.
Published: (2024-08-01)

Real-world outcomes of chemotherapy plus immune checkpoint inhibitors versus chemotherapy alone in advanced, unresectable, and recurrent intrahepatic cholangiocarcinoma
by: Tinotenda Blessing Madzikatire, et al.
Published: (2024-05-01)

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
by: Li J, et al.
Published: (2023-04-01)